Text Size

The Effect of Obesity on Growth Hormone Response to Anaerobic Exercise

This study is currently recruiting participants.
Verified March 2012 by Meir Medical Center
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01070589
First received: February 17, 2010
Last updated: March 16, 2012
Last verified: March 2012
History of Changes
  Purpose

The aim of the present study is to asses the effect of obesity on anaerobic exercise's growth hormone (GH) response.


Condition
Obesity

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Effect of Obesity on Growth Hormone Response to Anaerobic Exercise

Resource links provided by NLM:

Drug Information available for: Somatropin
U.S. FDA Resources

Further study details as provided by Meir Medical Center:

Estimated Enrollment: 24
Study Start Date: February 2010
Estimated Study Completion Date: July 2012
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Group 1: Obese
BMI>30
Group 2: control
Group 2:Normal weight (BMI <25). age and gender matched.

Detailed Description:

Exercise is a potent physiological stimulator of growth hormone (GH) release. GH is an important factor in the distribution of fat and lean tissue in the body. Previous studies suggested that the GH response to aerobic exercise may be attenuated by obesity. The effect of obesity on GH response to anaerobic effort is unclear. The aim of the present study is to asses the effect of obesity on anaerobic exercise's GH response. We will recruit 12 obese (BMI > 30) healthy adults and 12 age and gender matched normal weight (BMI < 25) controls. All the participants will conduct a "wingate" anaerobic test (30 seconds of intense effort against resistance calculated by the individual's body weight). Blood sample for GH level will be collected at 5 different time (0, 20, 30, 40 and 60 minutes after the test). We will compare the GH response in the two groups.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Healthy female Age 18-40 years

Criteria

Inclusion Criteria:

  • Healthy female
  • Age 18-40

Exclusion Criteria:

  • Male
  • Age <18, >40
  • Heart, Liver, Kidney or Hypophyseal disease
  • Medications that may alter GH secretion (eg Steroids, Eltroxin)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01070589

Contacts
Contact: Noa rakover klein, MD 972-77-4920014 noa.rakover@gmail.com

Locations
Israel
Meir Medical Center Recruiting
Kfar Saba, Israel
Contact: Noa rakover klein, MD     974-9-7472630     NOA.KLEIN@clalit.org.il    
Principal Investigator: Noa Klein, MD            
Sponsors and Collaborators
Meir Medical Center
Investigators
Principal Investigator: Allon Eliakim, MD Meir Medical Center
  More Information

No publications provided

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01070589     History of Changes
Other Study ID Numbers: MMC01922009CTIL
Study First Received: February 17, 2010
Last Updated: March 16, 2012
Health Authority: Israel: Ministry of Health

Keywords provided by Meir Medical Center:
Obesity
Growth hormone secretion
Anaerobic exercise

Additional relevant MeSH terms:
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
 Signs and Symptoms
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 18, 2013